BWAYNasdaqSurgical & Medical Instruments & ApparatusAlso trades as BRSYF

Brainsway Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 20, 2026

$11.99+0.55 (+4.81%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 66.6
Dividend yield: –

Brainsway Ltd. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	52	41	32	27	30	22	23	16	11
Cost of Revenue	13	10	8.31	7.13	6.60	5.06	5.13	3.59	2.60
Gross Profit	39	31	23	20	23	17	18	13	8.55
Research & Development	9.60	7.19	6.67	7.68	6.39	5.82	7.88	6.16	5.34
Selling & Marketing	19	16	16	18	16	11	13	8.35	6.33
Operating Expenses	35	29	28	33	28	22	26	18	15
Operating Income	4.32	1.39	-4.96	-13	-5.00	-4.83	-8.48	-5.11	-6.61
Interest Expense	2.21	1.52	1.16	1.47	-1.68	0.32	1.43	1.16	0.27
Interest & Investment Income	5.60	3.58	2.17	1.12	0.26	–	–	–	–
Pretax Income	7.71	3.46	-3.95	-13	-6.42	-5.15	-9.91	-6.27	-6.89
Income Tax Expense	0.14	0.54	0.25	0.32	0.04	0.24	0.42	0.21	0.17
Net Income incl. Noncontrolling Interests	7.58	2.92	-4.20	-13	-6.46	-5.39	-10	-6.48	-7.05
EPS (Basic)(per share)	0.20	0.09	-0.13	-0.40	-0.21	-0.24	-0.50	-0.39	-0.48
EPS (Diluted)(per share)	0.18	0.05	-0.13	-0.40	-0.21	-0.24	-0.50	-0.39	-0.48
Shares Outstanding (Basic, Weighted)(shares)	38	34	33	33	31	22	21	17	15
Shares Outstanding (Diluted, Weighted)(shares)	38	34	33	33	31	22	21	17	15
EBITDA	4.99	2.05	-4.60	-12	-4.44	-4.39	-7.93	-4.65	-6.22

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 75.4%
Operating margin: 8.3%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 3.59
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 273.9%

Valuation

P/E ratio: 66.6
Price to sales: –
Price to book: –
Dividend yield: –